Tranexamic Acid for the Prevention and Treatment of Postpartum Hemorrhage: A Systematic Review of Randomized Controlled Trials
DOI:
https://doi.org/10.35730/aax01866Keywords:
Tranexamic acid, postpartum hemorrhage, obstetrics, systematic review, randomized controlled trialAbstract
Background: Postpartum hemorrhage (PPH) is a leading cause of maternal death worldwide. Tranexamic acid (TXA), an antifibrinolytic agent, has been evaluated for both treatment and prevention of PPH in randomized controlled trials (RCTs). This systematic review summarizes its efficacy and safety.
Methods: Placebo-controlled RCTs of intravenous TXA in women giving birth, either with PPH (treatment) or at risk of PPH (prevention), were eligible. Data were extracted and synthesized without meta-analysis following the SWiM reporting guideline, with trials grouped by treatment or prevention and with qualitative risk-of-bias appraisal using RoB 2 domains.
Findings: Three RCTs (WOMAN, TRAAP, TRAAP2; 28,690 randomized women) were included. In WOMAN, TXA did not reduce death or hysterectomy (RR 0.97, 95% CI 0.87–1.09) but reduced death due to bleeding (RR 0.81, 95% CI 0.65–1.00), especially when given within 3 hours of birth (RR 0.69, 95% CI 0.52–0.91). For prevention, TXA did not significantly reduce blood loss ≥500 mL after vaginal birth (RR 0.83, 95% CI 0.68–1.01) but reduced PPH after cesarean delivery (adjusted RR 0.84, 95% CI 0.75–0.93). Nausea and vomiting were more frequent with TXA.
Conclusion: TXA given early reduces bleeding-related death in PPH, and may reduce PPH after cesarean delivery; evidence for prevention after vaginal birth is not conclusive.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Mikhail Nurhari, Cynthia Isra Mandahuta, Ismul Sadly (Author)

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.